First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

por Ready, Neal E, Audigier-Valette, Clarisse, Goldman, Jonathan W, Felip, Enriqueta, Ciuleanu, Tudor-Eliade, Rosario García Campelo, María, Jao, Kevin, Barlesi, Fabrice, Bordenave, Stéphanie, Rijavec, Erika, Urban, Laszlo, Aucoin, Jean-Sébastien, Zannori, Cristina, Vermaelen, Karim, Arén Frontera, Osvaldo, Curioni Fontecedro, Alessandra, Sánchez-Gastaldo, Amparo, Juan-Vidal, Oscar, Linardou, Helena, Poddubskaya, Elena, Spigel, David R, Ahmed, Samreen, Maio, Michele, Li, Sunney, Chang, Han, Fiore, Joseph, Acevedo, Angelic, Paz-Ares, Luis
Publicado 2023

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

por Cortellini, Alessio, Buti, Sebastiano, Bersanelli, Melissa, Giusti, Raffaele, Perrone, Fabiana, Di Marino, Pietro, Tinari, Nicola, De Tursi, Michele, Grassadonia, Antonino, Cannita, Katia, Tessitore, Alessandra, Zoratto, Federica, Veltri, Enzo, Malorgio, Francesco, Russano, Marco, Anesi, Cecilia, Zeppola, Tea, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Cappellini, Gian Carlo Antonini, De Galitiis, Federica, Vitale, Maria Giuseppa, Rastelli, Francesca, Pergolesi, Federica, Berardi, Rossana, Rinaldi, Silvia, Tudini, Marianna, Silva, Rosa Rita, Pireddu, Annagrazia, Atzori, Francesco, Iacono, Daniela, Migliorino, Maria Rita, Gelibter, Alain, Occhipinti, Mario Alberto, Martella, Francesco, Inno, Alessandro, Gori, Stefania, Bracarda, Sergio, Zannori, Cristina, Mosillo, Claudia, Parisi, Alessandro, Porzio, Giampiero, Mallardo, Domenico, Fargnoli, Maria Concetta, Tiseo, Marcello, Santini, Daniele, Ascierto, Paolo A, Ficorella, Corrado
Publicado 2020